2-[[4-[2-[1,3-Benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-[[4-[2-[1,3-Benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione
• 化学式: C₁₉H₁₈N₄O₅
• 分子量: 382.376
• InChiKey: LLNXHJQBGYOROM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]-benzaldehyde 在 盐酸 、 盐酸羟胺 、 sodium acetate 、 methyl orange 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 生成 2-[[4-[2-[1,3-Benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione
  参考文献：
  名称：

  Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

  摘要：

  A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg(-1) oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg(-1) oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg(-1) oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg(-1) oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg(-1) oral dose. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)01191-0

文献信息

• A Versatile Route to 2-Arylmethyl-1,2,4-oxadiazolidine-3,5-diones <i>via</i> Regiospecific Alkylation of 1,2,4-Oxadiazolidine-3,5-dione
  作者：Barrie Cantello、Susan Connor、David Dean、Richard Hindley

  DOI：10.1055/s-1997-772

  日期：1997.3

  2-Arylmethyl-1,2,4-oxadiazolidine-3,5-diones can be prepared in a single step by the regiospecific alkylation of 1,2,4-oxadiazolidine-3,5-dione with substituted benzyl halides.

  2-Arylmethyl-1,2,4-oxadiazolidine-3,5-diones可以通过1,2,4-oxadiazolidine-3,5-dione与取代的苄基卤化物的区域选择性烷基化一步制备。
• Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones
  作者：M Malamas

  DOI：10.1016/s0223-5234(00)01191-0

  日期：2001.1

  A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg(-1) oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg(-1) oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg(-1) oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg(-1) oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg(-1) oral dose. (C) 2001 Editions scientifiques et medicales Elsevier SAS.